Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRIORITY: Dalteparin vs DOACs for VTE in GI and Hepatobiliary Cancers
NCT03139487Phase 2Unknown
- Sponsor
- Asan Medical Center
- Start
- Aug 2017
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban, apixaban in venous thromboembolism (VTE), sponsored by Asan Medical Center. Status: unknown.
02
Drugs
rivaroxabanapixaban
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT03139487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03139487.